SHPH SHUTTLE PHARMACEUTICALS HOLDINGS INC US FDA Inspections 8-K Filing 2024 - FDA Approval for Phase II Study of Ropidoxuridine Shuttle Pharmaceuticals received FDA approval for its Phase II study of Ropidoxuridine as a radiation sensitizing agent in glioblastoma patients.Get access to all SEC 8-K filings of the SHUTTLE PHARMACEUTICALS HOLDINGS INC